The PI3K/Akt/mTOR axis in head and neck cancer: Functions, aberrations, cross-talk, and therapies

Oral Diseases

Volumn 21, Issue 7, 2015, Pages 815-825

  Vander Broek, R ^a,b,c   Mohan, S ^a,b   Eytan, D F ^a,b   Chen, Z ^a   Van Waes, C ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

Akt; Head and neck cancer; MTOR; NF B; P53; PI3K

Indexed keywords

2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXY 3 PYRIDINYL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALPELISIB; BUPARLISIB; DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; GEDATOLISIB; MAMMALIAN TARGET OF RAPAMYCIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; RAPAMYCIN; SONOLISIB; TEMSIROLIMUS; VOXTALISIB; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

CANCER GROWTH; CARCINOGENESIS; COPY NUMBER VARIATION; DISEASE ASSOCIATION; GENE DOSAGE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INFLAMMATION; LYMPH NODE METASTASIS; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; NEOVASCULARIZATION (PATHOLOGY); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; GENETIC VARIATION; GENETICS; HEAD AND NECK NEOPLASMS; METABOLISM;

CARCINOMA, SQUAMOUS CELL; GENETIC VARIATION; HEAD AND NECK NEOPLASMS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR CROSS-TALK; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84941744367     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12206     Document Type: Review

References (129)

1. Abraham RT (2004). mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 279: 299-319.
2. Agrawal N, Frederick MJ, Pickering CR et al (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
3. Ahmed O, Kuo WL, Nagilla M et al (2013). Synergy with combination of AKT inhibitor (MK-2206) and paclitaxel in head and neck squamous cell carcinoma. J Clin Oncol 31, Abstract e13532.
4. Allen C, Duffy S, Teknos T et al (2007). Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 13: 3182-3190.
5. Amornphimoltham P, Sriuranpong V, Patel V et al (2004). Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10: 4029-4037.
6. Amornphimoltham P, Patel V, Sodhi A et al (2005). Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck. Cancer Res 65: 9953-9961.
7. Argiris A, Cohen E, Karrison T et al (2006). A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. Cancer Biol Ther 5: 766-770.
8. Baish JW, Stylianopoulos T, Lanning RM et al (2011). Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci USA 108: 1799-1803.
9. Bancroft CC, Chen Z, Yeh J et al (2002). Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548.
10. Bellacosa A, Testa JR, Staal SP, Tsichlis PN (1991). A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. Science 254: 274-277.
11. Bhaskar PT, Hay N (2007). The two TORCs and Akt. Dev Cell 12: 487-502.
12. Bian Y, Hall B, Sun ZJ et al (2012). Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 31: 3322-3332.
13. Carracedo A, Ma L, Teruya-Feldstein J et al (2008). Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Investig 118: 3065-3074.
14. Carroll PE, Okuda M, Horn HF et al (1999). Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 18: 1935-1944.
15. Chen Z, Colon I, Ortiz N et al (1998). Effects of interleukin-1alpha, interleukin-1 receptor antagonist, and neutralizing antibody on proinflammatory cytokine expression by human squamous cell carcinoma lines. Cancer Res 58: 3668-3676.
16. Chen Z, Malhotra PS, Thomas GR et al (1999). Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-1379.
17. Cohen Y, Goldenberg-Cohen N, Shalmon B et al (2011). Mutational analysis of PTEN/PIK3CA/AKT pathway in oral squamous cell carcinoma. Oral Oncol 47: 946-950.
18. Courtney KD, Corcoran RB, Engelman JA (2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083.
19. Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP, Baldwin AS (2008). Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 22: 1490-1500.
20. Di Maira G, Salvi M, Arrigoni G et al (2005). Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12: 668-677.
21. Domin J, Waterfield MD (1997). Using structure to define the function of phosphoinositide 3-kinase family members. FEBS Lett 410: 91-95.
22. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C (2001a). Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res 61: 5911-5918.
23. Dong G, Loukinova E, Chen Z et al (2001b). Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-kappaB signal pathway. Cancer Res 61: 4797-4808.
24. Du W, Yi Y, Zhang H et al (2013). Rapamycin inhibits IGF-1-mediated up-regulation of MDM2 and sensitizes cancer cells to chemotherapy. PLoS ONE 8: e63179.
25. Duffey DC, Chen Z, Dong G et al (1999). Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo. Cancer Res 59: 3468-3474.
26. Ekshyyan O, Mills GM, Lian T et al (2010). Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma. Head Neck 32: 1619-1628.
27. Engelman JA (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
28. Engelman JA, Luo J, Cantley LC (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606-619.
29. Ercan D, Xu C, Yanagita M et al (2012). Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2: 934-947.
30. Fenic I, Steger K, Gruber C, Arens C, Woenckhaus J (2007). Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma. Oncol Rep 18: 253-259.
31. Freudlsperger C, Burnett JR, Friedman JA, Kannabiran VR, Chen Z, Van Waes C (2011). EGFR-PI3K-AKT-mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy. Expert Opin Ther Targets 15: 63-74.
32. Friedman JA, Wise SC, Hu M et al (2013). HSP90 inhibitor SNX5422/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma. Transl Oncol 6: 429-441.
33. Fruman DA, Rommel C (2011). PI3Kdelta inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov 1: 562-572.
34. Fruman DA, Meyers RE, Cantley LC (1998). Phosphoinositide kinases. Annu Rev Biochem 67: 481-507.
35. Fury MG, Lee NY, Sherman E et al (2013a). A Phase 1 Study of Everolimus + Weekly Cisplatin + Intensity Modulated Radiation Therapy in Head-and-Neck Cancer. Int J Radiat Oncol Biol Phys 87: 479-486.
36. Fury MG, Sherman E, Ho AL et al (2013b). A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 119: 1823-1831.
37. Gillison ML, Koch WM, Capone RB et al (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720.
38. Gingras AC, Raught B, Sonenberg N (1999). eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963.
39. Gonzalez-Angulo A (2013). Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: results from the first-in-human study. J Clin Oncol 31, Abstract 2531.
40. Grandis JR, Hayes DN, El-Naggar AK, and The Cancer Genome Atlas Group (2012). Comprehensive genomic characterization of squamous cell carcinoma of the head and neck. TCGA 2nd Annual Scientific Symposium: 32
41. Graupera M, Guillermet-Guibert J, Foukas LC et al (2008). Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453: 662-666.
42. Grivennikov SI, Greten FR, Karin M (2010). Immunity, inflammation, and cancer. Cell 140: 883-899.
43. Gustin JA, Ozes ON, Akca H et al (2004). Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem 279: 1615-1620.
44. Hamada K, Sasaki T, Koni PA et al (2005). The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev 19: 2054-2065.
45. Hayes DN, Grandis JR, El-Naggar AK (2013). Comprehensive genomic characterization of squamous cell carcinoma of the head and neck in the Cancer Genome Atlas. American Association for Cancer Research Annual Meeting, Washington, DC: Abstract 1117.
46. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005). Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discovery 4: 988-1004.
47. Herzog A, Bian Y, Vander Broek R et al (2013). PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer. Clin Cancer Res 19: 3808-3819.
48. Hideshima T, Catley L, Yasui H et al (2006). Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-4062.
49. Hong DS, Bowles DW, Falchook GS et al (2012). A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 18: 4173-4182.
50. Huang J, Manning BD (2009). A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 37: 217-222.
51. Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS (2012). Oncogenic PI3K mutations lead to NF-kappaB-dependent cytokine expression following growth factor deprivation. Cancer Res 72: 3260-3269.
52. Iglesias-Bartolome R, Martin D, Gutkind JS (2013). Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. Cancer Discov 3: 722-725.
53. Inoki K, Corradetti MN, Guan KL (2005). Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 37: 19-24.
54. Juric D, Rodon J, Gonzalez-Angulo AM et al (2012). BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research: Abstract CT-01.
55. Kalaany NY, Sabatini DM (2009). Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-731.
56. Kalyankrishna S, Grandis JR (2006). Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24: 2666-2672.
57. Kang SA, Pacold ME, Cervantes CL et al (2013). mTORC1 phosphorylation sites encode their sensitivity to starvation and rapamycin. Science 341: 1236566.
58. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615-675.
59. Kavitha K, Kowshik J, Kishore TK, Baba AB, Nagini S (2013). Astaxanthin inhibits NF-kappaB and Wnt/beta-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer. Biochim Biophys Acta 1830: 4433-4444.
60. Keysar SB, Astling DP, Anderson RT et al (2013). A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Molecular oncology 7: 776-790.
61. Kolsch V, Charest PG, Firtel RA (2008). The regulation of cell motility and chemotaxis by phospholipid signaling. J Cell Sci 121: 551-559.
62. Koyasu S (2003). The role of PI3K in immune cells. Nat Immunol 4: 313-319.
63. Kozaki K, Imoto I, Pimkhaokham A et al (2006). PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma. Cancer Sci 97: 1351-1358.
64. Lee JI, Soria JC, Hassan KA et al (2001). Loss of PTEN expression as a prognostic marker for tongue cancer. Arch Otolaryngol Head Neck Surg 127: 1441-1445.
65. Lee TL, Yeh J, Friedman J et al (2008). A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer 122: 1987-1998.
66. Leemans CR, Braakhuis BJ, Brakenhoff RH (2011). The molecular biology of head and neck cancer. Nat Rev Cancer 11: 9-22.
67. Li Y, Corradetti MN, Inoki K, Guan KL (2004). TSC2: filling the GAP in the mTOR signaling pathway. Trends Biochem Sci 29: 32-38.
68. Limesand KH, Chibly AM, Fribley A (2013). Impact of targeting insulin-like growth factor signaling in head and neck cancers. Growth Horm IGF Res 23: 135-140.
69. Liu P, Cheng H, Roberts TM, Zhao JJ (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discovery 8: 627-644.
70. LoRusso P, Britten C, Millham R et al (2011). First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics: Abstract B163.
71. Loukinova E, Dong G, Enamorado-Ayalya I et al (2000). Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 19: 3477-3486.
72. Lu C, Mi LZ, Schurpf T, Walz T, Springer TA (2012). Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor. J Biol Chem 287: 38244-38253.
73. Luangdilok S, Box C, Harrington K, Rhys-Evans P, Eccles S (2011). MAPK and PI3K signalling differentially regulate angiogenic and lymphangiogenic cytokine secretion in squamous cell carcinoma of the head and neck. Eur J Cancer 47: 520-529.
74. Lui VW, Hedberg ML, Li H et al (2013). Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3: 761-769.
75. Manning BD, Cantley LC (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
76. Martin-Belmonte F, Mostov K (2008). Regulation of cell polarity during epithelial morphogenesis. Curr Opin Cell Biol 20: 227-234.
77. Massarelli E, Liu DD, Lee JJ et al (2005). Akt activation correlates with adverse outcome in tongue cancer. Cancer 104: 2430-2436.
78. Mayo LD, Donner DB (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603.
79. Mayo LD, Donner DB (2002). The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 27: 462-467.
80. McBride SM, Rothenberg SM, Faquin WC et al (2013). Mutation frequency in 15 common cancer genes in high-risk head and neck squamous cell carcinoma (HNSCC). Head Neck [Epub ahead of print]. PMID 23852799.
81. Meyuhas O (2000). Synthesis of the translational apparatus is regulated at the translational level. Euro J Bioche FEBS 267: 6321-6330.
82. Molinolo AA, Hewitt SM, Amornphimoltham P et al (2007). Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 13: 4964-4973.
83. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS (2009). Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45: 324-334.
84. Morris LG, Taylor BS, Bivona TG et al (2011). Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers. Proc Natl Acad Sci USA 108: 19024-19029.
85. Murugan AK, Hong NT, Fukui Y, Munirajan AK, Tsuchida N (2008). Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas. Int J Oncol 32: 101-111.
86. Nathan CO, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J (1999). Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. J Clin Oncol 17: 2909-2914.
87. Nathan CO, Amirghahari N, Abreo F et al (2004). Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway. Clin Cancer Res 10: 5820-5827.
88. Nichols AC, Palma DA, Chow W et al (2013). High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol Head Neck Surg 139: 617-622.
89. Normanno N, De Luca A, Bianco C et al (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366: 2-16.
90. Nottingham LK, Yan CH, Yang X et al (2013). Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene [Epub ahead of print]. PMID 23455325.
91. Okami K, Wu L, Riggins G et al (1998). Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res 58: 509-511.
92. O'Reilly KE, Rojo F, She QB et al (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
93. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB (1999). NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401: 82-85.
94. Pan D, Dong J, Zhang Y, Gao X (2004). Tuberous sclerosis complex: from Drosophila to human disease. Trends Cell Biol 14: 78-85.
95. Patel V, Marsh CA, Dorsam RT et al (2011). Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 71: 7103-7112.
96. Pernas FG, Allen CT, Winters ME et al (2009). Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 15: 2361-2372.
97. Pickering CR, Zhang J, Yoo SY et al (2013). Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3: 770-781.
98. Qiu W, Schönleben F, Li X et al (2006). PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res 12: 1441-1446.
99. Raimondi AR, Molinolo A, Gutkind JS (2009). Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. Cancer Res 69: 4159-4166.
100. Raymond E, Tourneau CL, Gatineau M et al (2013). CAPRA: Safety, efficacy, and translational biomarkers of weekly everolimus, carboplatin, and paclitaxel as induction therapy for locally advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 31, Abstract 6036.
101. Redon R, Muller D, Caulee K, Wanherdrick K, Abecassis J, du Manoir S (2001). A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains. Cancer Res 61: 4122-4129.
102. Rogers SJ, Harrington KJ, Rhys-Evans P, O-Charoenrat P, Eccles SA (2005). Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer Metastasis Rev 24: 47-69.
103. Romashkova JA, Makarov SS (1999). NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401: 86-90.
104. Rommel C, Camps M, Ji H (2007). PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nature reviews. Immunology 7: 191-201.
105. Samuels Y, Wang Z, Bardelli A et al (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
106. Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al (2005). Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561-573.
107. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
108. Scheid MP, Woodgett JR (2001). PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2: 760-768.
109. Schmid MC, Avraamides CJ, Dippold HC et al (2011). Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19: 715-727.
110. Sen M, Joyce S, Panahandeh M et al (2012). Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 18: 4986-4996.
111. Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin 63: 11-30.
112. Singh B, Reddy PG, Goberdhan A et al (2002). p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev 16: 984-93.
113. Squarize CH, Castilho RM, Santos Pinto D Jr (2002). Immunohistochemical evidence of PTEN in oral squamous cell carcinoma and its correlation with the histological malignancy grading system. J Oral Pathol Med 31: 379-384.
114. Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW, Gutkind JS (2013). PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia 15: 461-471.
115. Stransky N, Egloff AM, Tward AD et al (2011). The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
116. Su JD, Mayo LD, Donner DB, Durden DL (2003). PTEN and phosphatidylinositol 3′-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 63: 3585-3592.
117. Suda T, Hama T, Kondo S et al (2012). Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma. BMC Cancer 12: 416.
118. Tabernero J, Bell-McGuinn K, Bendell J et al (2011). First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: update on safety, efficacy, and pharmacology. AACR-NCI-EORTC International Conference: Molecular Cancer Therapy: Abstract A167.
119. Van Waes C (2007). Nuclear factor-kappaB in development, prevention, and therapy of cancer. Clin Cancer Res 13: 1076-1082.
120. Van Waes C, Yu M, Nottingham L, Karin M (2007). Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res 13: 4956-4959.
121. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC (2005). Signalling by PI3K isoforms: insights from gene-targeted mice. Trends Biochem Sci 30: 194-204.
122. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 11: 329-341.
123. Vanhaesebroeck B, Stephens L, Hawkins P (2012). PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 13: 195-203.
124. Vivanco I, Sawyers CL (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
125. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW (2013). Cancer genome landscapes. Science 339: 1546-1558.
126. Woenckhaus J, Steger K, Werner E et al (2002). Genomic gain of PIK3CA and increased expression of p110alpha are associated with progression of dysplasia into invasive squamous cell carcinoma. J Pathol 198: 335-342.
127. Yang CH, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM (2001). Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem 276: 13756-13761.
128. Yuan TL, Cantley LC (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
129. Yuan TL, Choi HS, Matsui A et al (2008). Class 1A PI3K regulates vessel integrity during development and tumorigenesis. Proc Natl Acad Sci USA 105: 9739-9744.